Navigation Links
ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
Date:9/18/2008

Company CEO is featured speaker: "Case Study - Screening Ion Channels for

Safety and Efficacy" on Friday, September 26 at 11:30

CLEVELAND, Sept. 18 /PRNewswire/ -- ChanTest will feature its expanding line of ion channel services and cell lines for drug-discovery and development applications in booth 11 at the Assays and Cellular Targets conference in San Diego, September 24-26. ChanTest designed its ion channel cell lines and services to provide drug-discovery researchers the early information they need to identify the most promising target compounds and eliminate those that could ultimately cause harmful side effects. ChanTest is also working with pharmaceutical and biotech companies to help rescue shelved pharmaceutical compounds.

Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will present a case study to conference participants entitled, "Screening Ion Channels for Safety and Efficacy," on Friday, September 26 at 11:30, as part of the conference's Ion Channel Targets track. "We are developing a library of ion channel-expressing cell lines for screening with the full range of automated patch clamp instruments and FLIPR-Tetra(r)," said Dr. Brown. "At present, 86 'books' are available and 160 will be available by June 2009. We validate each cell line for cDNA sequence, Western blot, voltage range, gating, and pharmacology. We recognize that each research program has its own unique needs and priorities, so we've designed our services and cell lines to offer the most flexibility possible. Our validated ion channels can be mixed and matched into panels according to tissue, e.g., cardiac; therapeutic area, e.g., pain; and ion channel family, e.g., TRP channels. And we draw upon our years of ion channel experience to help customers design an appropriate testing program to meet their specific scientific and budgetary goals."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

The A/C/T Assays and Cellular Targets conference and exhibition takes place September 24-26, 2008 at the Marriott San Diego Hotel & Marina in California.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 18,000 compounds for more than 250 global pharmaceutical and biotech companies - helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
2. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
3. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
4. ChanTest Launches Redesigned Web Site
5. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
9. Neuralstem Reports Second Quarter Financial Results and Highlights
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016  The Allen Institute for ... the first publicly available collection of gene edited, ... target key cellular structures with unprecedented clarity. Distributed ... powerful tools are a crucial first step toward ... understand what makes human cells healthy and what ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a ... cancer care, and Penn,s Abramson Cancer Center have ... a positive response to immunotherapy treatment based on ... As part of a research collaboration, Tempus ... and melanoma cancer patient data to Penn. Utilizing ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... --  Merck , a leading science and technology company, ... of agreements with Evotec AG, whereby Evotec AG will ... such as CRISPR and shRNA libraries. Combining access to ... pathway to explore and identify new drug targets. ... targets, a process that can be time- and labor-intensive," ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):